Tango Therapeutics director granted RSUs, options

Tango Therapeutics director Mace Rothenberg reported equity awards in the form of restricted stock units and stock options.

Rhea-AI Filing Summary

Tango Therapeutics director Mace Rothenberg reported equity awards in the form of restricted stock units and stock options. The filing shows a grant of 4,000 shares of Common Stock represented by restricted stock units, plus a stock option for 25,000 shares at an exercise price of $20.2200 per share.

The restricted stock units vest in full on the earlier of June 5, 2027 or the next annual meeting of stockholders, subject to continuous service. The option vests in 12 substantially equal monthly installments over one year starting on July 5, 2026 and expires on June 5, 2036. After the stock grant, Rothenberg holds 41,500 shares of Common Stock directly.

Insider Trade Summary

Grant/Award: 29,000 shares

Grant/Award 2 txns

Insider Rothenberg Mace

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,000	$0.00	$0.00
Grant/Award	Common Stock	4,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 25,000 contracts (Direct); Common Stock — 41,500 shares (Direct)

Footnotes (2)

1. F1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
2. F2. This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Key Figures

Restricted stock units granted: 4,000 shares Stock options granted: 25,000 options Option exercise price: $20.2200 per share +4 more

7 metrics

Restricted stock units granted 4,000 shares RSUs representing Common Stock granted on June 5, 2026

Stock options granted 25,000 options Stock Option (Right to Buy) granted on June 5, 2026

Option exercise price $20.2200 per share Conversion or exercise price of stock option

Shares held after grant 41,500 shares Common Stock directly owned after the RSU grant

Option expiration date June 5, 2036 Expiration of 25,000-share stock option

Option vesting start July 5, 2026 First monthly vesting date for stock option

RSU vesting date June 5, 2027 or next annual meeting RSUs vest in full on the earlier of these dates

Key Terms

restricted stock units, Stock Option (Right to Buy), exercise price, vest, +1 more

5 terms

restricted stock units financial

"These shares are represented by restricted stock units (the "RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "20.2200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"This option shall vest and become exercisable in 12 substantially equal monthly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Tango Therapeutics (TNGX) director Mace Rothenberg receive?

Mace Rothenberg received 4,000 shares of Common Stock represented by restricted stock units and a stock option for 25,000 shares. The option carries an exercise price of $20.2200 per share and is structured as a time-based vesting award.

How do Mace Rothenberg’s new restricted stock units in Tango Therapeutics (TNGX) vest?

The 4,000 restricted stock units vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders. Vesting is conditioned on Rothenberg’s continuous service with Tango Therapeutics through the applicable vesting date.

What are the vesting terms of Mace Rothenberg’s new Tango Therapeutics (TNGX) stock option?

The 25,000-share stock option vests in 12 substantially equal monthly installments over one year, starting July 5, 2026. Each installment requires Rothenberg to remain in continuous service with Tango Therapeutics through the applicable monthly vesting date.

What is the exercise price and expiration date of Mace Rothenberg’s Tango Therapeutics stock option?

The stock option has an exercise price of $20.2200 per share and covers 25,000 shares of Common Stock. It is scheduled to expire on June 5, 2036, if not earlier exercised or forfeited under its terms.

How many Tango Therapeutics (TNGX) shares does Mace Rothenberg hold after these awards?

Following the reported stock grant, Mace Rothenberg directly holds 41,500 shares of Tango Therapeutics Common Stock. This figure reflects his position after receiving the 4,000-share restricted stock unit award reported in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 05:55 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rothenberg Mace

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.,

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		4,000(1)	A	$0	41,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20.22	06/05/2026		A		25,000		(2)	06/05/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

2. This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Julie Fogarty, as attorney-in-fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)